Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Quality of Life in Atopic Dermatitis
NCT03667014Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Nov 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by University of California, San Francisco. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03667014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667014.